GeneDx completed a significant acquisition of Fabric Genomics in May 2025, substantially expanding operations and financial scale across all key metrics.
The acquisition of Fabric Genomics represents a transformative transaction that meaningfully expanded GeneDx's business scale, with revenue growing 40% and the company showing improved operational leverage through substantially higher gross profits. The integration appears successful given the improved loss position and stronger balance sheet, though investors should monitor the company's ability to integrate the substantially higher R&D expenses and working capital requirements.
The Fabric Genomics acquisition drove substantial growth across GeneDx's financial profile, with revenue expanding 40% to $427.5M and gross profits growing meaningfully to $298.2M. Balance sheet items roughly doubled in scale, including current liabilities and accounts receivable, reflecting the enlarged operational footprint, while stockholders' equity increased 25.7% to $308.2M. Despite substantially higher R&D spending, the company improved its net loss position and operating performance, suggesting successful integration and operational leverage from the combination.
Current liabilities surged 98.7% — significant near-term obligations; verify ability to meet short-term debt.
Receivables surged 97.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income grew 59.8% — bottom-line growth signals improving overall business health.
R&D investment increased 57.5% — signals commitment to future product development, though near-term margin impact.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Strong top-line growth of 40% — accelerating demand or successful expansion into new markets.
Current assets grew 35.5% — improving short-term liquidity or inventory/receivables build.
Inventory surged 31% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
Equity base grew 25.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →